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Abstract This work presents a comparison between three analytical methods 14 
developed for the simultaneous determination of eight quinolones regulated by the 15 
European Union (marbofloxacin, ciprofloxacin, danofloxacin, enrofloxacin, difloxacin, 16 
sarafloxacin, oxolinic acid and flumequine) in pig muscle, using liquid chromatography 17 
with fluorescence detection (LC–FD), liquid chromatography-mass spectrometry (LC–18 
MS) and liquid chromatography-tandem mass spectrometry (LC–MS/MS). The 19 
procedures involve an extraction of the quinolones from the tissues, a step for clean–up 20 
and preconcentration of the analytes by solid–phase extraction (SPE) and a subsequent 21 
liquid chromatographic analysis. The limits of detection of the methods ranged from 0.1 22 
to 2.1 ng g–1 using LC–FD, from 0.3 to 1.8 using LC–MS and from 0.2 to 0.3 using LC–23 
MS/MS, while inter- and intra-day variability was under 15% in all cases. Most of those 24 
data are notably lower than the maximum residue limits (MRL) established by the 25 
European Union for quinolones in pig tissues. The methods have been applied for the 26 
determination of quinolones in six different commercial pig muscle samples purchased 27 
in different supermarkets located in the city of Granada (South-East Spain). 28 
 29 
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Introduction 44 
 45 
The research in the field of contamination in foods has extended in the last years beyond 46 
classical contaminants–pesticides, biocides, polyaromatic hydrocarbons, dioxins or 47 
polychlorinated biphenyls–to other compounds such as pharmaceuticals or personal care 48 
products [1]. Since pharmaceuticals are produced and applied with the aim of being 49 
biologically active and stimulate a physiological response in human and animals even at 50 
low concentrations, there is a growing concern in relation to these substances and their 51 
recognition as contaminants, mainly due to the adverse effects that their wide use and 52 
disposal have on human health [2]. European consumption of pharmaceuticals is known 53 
to be increasing on a yearly basis, and today more than 5000 products are being used as 54 
painkillers, contraceptives, tranquilizers, lipid regulators, beta–blockers or antibiotics 55 
[1]. Antibiotics and their degradation metabolites rank among the most used drugs in 56 
human and veterinary medicine. Resistance to antibiotics and other anti–infective agents 57 
constitutes a major threat to public health and ought to be recognized as such more 58 
widely than it is currently. Therefore, the European Union (EU) recommends the 59 
prudent use of antimicrobial agent in human medicine.  60 
One of the most important groups of antibiotics is quinolones. They are a family 61 
of highly potent antibiotics with a broad spectrum of activity against both Gram–62 
negative and Gram–positive pathogens. They are widely used in human and veterinary 63 
medicine in the treatment of infections and represent an expanding class of broad–64 
spectrum antibacterials [3]. Quinolones have become an integral part of the livestock 65 
production industry and can be used therapeutically to treat disease or to prevent it as 66 
well as for promoting growth [4]. Their use in veterinary applications can result in the 67 
appearance of residues of the compounds and metabolites in edible animal meats and 68 
may give rise to public health concerns, including development of resistant bacterial 69 
strains, toxic effects or allergic hypersensitivity [5]. Some international organizations 70 
such as the World Health Organization (WHO) have recommended a higher attention 71 
and control in the use of antimicrobial growth promoters that belong to an antimicrobial 72 
class used in humans. The EU agreed to reduce the use of all antimicrobial growth 73 
promoters from 2002. To ensure safety, it has been established maximum residue limits 74 
(MRLs) for veterinary drugs in those animal tissues that enter the human food chain [6-75 
9]. The MRLs values of quinolones in pig muscle are lower than the ones established in 76 
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other tissues as kidney or liver. So, the MRL in pig muscle for enrofloxacin plus 77 
ciprofloxacin, danofloxacin and oxolinic acid are fixed at 100 ng g–1, for marbofloxacin 78 
and flumequine at 150 and 200 ng g–1 respectively, while for difloxacin the MRL is 400 79 
ng g–1. The MRL of sarafloxacin, major metabolite of difloxacin is not yet established. 80 
Therefore, more analytical methodology is demanded to quantify and confirm the 81 
identity of these compounds in food–producing animal. In the scientific literature, some 82 
analytical methodologies have been described for the determination of fluoroquinolone 83 
residues in animal derived foods. Given the complexity of these samples, the majority 84 
of these methodologies are based in the use of liquid chromatography (LC) with 85 
ultraviolet (UV) [10], fluorescence (FD) [11] or mass spectrometric (MS) detection [12] 86 
after sample clean–up by SPE [10-12]. Owing to its specificity, mass spectrometry is the 87 
most powerful confirmatory technique; however, it is expensive and thus not available 88 
to all laboratories. In the case of fluorescent drugs, as quinolones, because of its 89 
selectivity and sensitivity, FD is a very good detection approach. 90 
The main objective of this work is to compare the quality control parameters of 91 
three different analytical methodologies developed using LC–FD, LC–MS or LC–92 
MS/MS for the determination of quinolones in pig muscle samples in order to provide 93 
the method that has the best analytical characteristics. The three analytical 94 
methodologies were satisfactorily applied for the quantification of compounds in 95 
samples picked up at different supermarkets of Granada (Spain). 96 
 97 
 98 
Experimental 99 
 100 
Chemical and reagents 101 
 102 
Pure quinolone standards were purchased from different pharmaceutical companies. 103 
Ciprofloxacin (CIP) from Ipsen Pharma (Barcelona, Spain); danofloxacin (DAN) from 104 
Pfizer (Karlsruhe, Germany); difloxacin (DIF) and sarafloxacin (SAR) from Abbott 105 
(Madrid, Spain); enrofloxacina (ENR) from Cenavisa (Tarragona, Spain); flumequine 106 
(FLU), norfloxacina (NOR) and oxolinic acid (OXO) form Sigma–Aldrich (Madrid, 107 
Spain) and marbofloxacin (MAR) from Vetoquinol (Lure, France).  108 
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Acetonitrile, MeCN (LC–grade), o–phosphoric and citric acids were obtained 109 
from Panreac (Barcelona, Spain). Methanol, ethanol, hexane, ammonia, formic acid, 110 
trifluoroacetic acid and m–phosphoric acid were supplied by Merck (Darmstadt, 111 
Germany). Isolute ENV+ (200 mg/3 mL) solid–phase extraction (SPE) adsorbent 112 
cartridges were purchased from Isolute Sorbent Technologies (Mid Glamorgan, UK). 113 
 114 
Instrumentation and software 115 
 116 
LC–FD analysis were performed using an HP Agilent Technologies (Palo Alto, CA, 117 
USA) 1100 series liquid chromatography system with fluorescence detector connected 118 
on–line. ChemStation for LC 3D software (Agilent) was used for instrument control and 119 
for data acquisition and analysis. LC–MS and LC–MS/MS analysis were performed 120 
using an API 3000 (Applied Biosystems, Foster City, CA, USA) triple quadrupole mass 121 
spectrometer system. In order to obtain data, the Analyst 1.4 software was used. 122 
All pH measurements were made with a Crison (Crison Instruments S.A, 123 
Barcelona, Spain) combined glass–Ag/AgCl (KCl 3 M) electrode using a previously 124 
calibrated Crison 2000 digital pH–meter. A Branson digital sonifier (Danbury, CT, 125 
USA) and a Hettich Universal 32 centrifuge (Tuttlingen, Germany) were also used. SPE 126 
was performed on a Supelco (Madrid, Spain) vacuum manifold for 12 columns 127 
connected to a Supelco vacuum tank and to a vacuum pump. Statgraphics software was 128 
used for statistical and regression analysis. 129 
 130 
Preparation of standard and stock solutions 131 
 132 
For LC–MS and LC–MS/MS analyses individual stock solutions of CIP, DAN, DIF, 133 
ENR, MAR, NOR, and SAR (100 µg mL–1), were prepared in 50 mM acetic acid 134 
aqueous solution. FLU and OXO (100 µg mL–1) were prepared in MeCN. Individual 135 
working solutions were prepared by diluting the initial standard solutions with MeCN.  136 
For LC–FD analysis, individual stock solutions of CIP, DAN, DIF, ENR, MAR, 137 
NOR and SAR (100 µg mL–1) were prepared in ethanol (99.9% v/v). Individual stock 138 
solutions of FLU and OXO (100 µg mL–1) were prepared in MeCN. Individual working 139 
solutions were prepared by diluting suitably with a MeCN–water mixture (12:88, v/v). 140 
All solutions were stored at 4 ºC in the dark for not longer than 2 months.  141 
 142 
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Preparation of fortified samples 143 
 144 
Fortified samples were prepared by spiking 5 g (accurately weighed) of minced blank 145 
pig muscle adding the adequate volumes of working solutions of studied quinolones and 146 
norfloxacin –a forbidden veterinary quinolone– used as surrogate. Before sample 147 
treatment and analysis, all samples were allowed to stand in the dark for 20 min at room 148 
temperature to permit the total interaction between the antibiotics and tissues. In order 149 
to evaluate recoveries, spiked samples in the same range of concentration were prepared 150 
and compared with samples spiked after the SPE procedure and that were considered 151 
the 100% of recovery. 152 
 153 
Basic procedure 154 
 155 
Two methods previously published by the authors were followed for sample treatment 156 
[11, 12]. The procedures involve an extraction of the quinolones from the tissues by 157 
shaking, a clean–up and preconcentration step by solid–phase extraction (SPE) and a 158 
subsequent liquid chromatographic analysis. 159 
 160 
 161 
Results and discussion 162 
 163 
Validation of the methods 164 
 165 
Analytical performance 166 
 167 
For LC–MS/MS calibration, the studied concentration levels ranged from 0.5 to 100.0 168 
ng g–1; for LC LC–MS from 5.0 to 100.0 and for LC–FD from 5.0 to 50.0. In all cases 169 
each level of concentration was made in duplicate. Calibration curves were constructed 170 
using analyte/surrogate peak area ratio versus concentration of analyte. Norfloxacin 171 
(400 ng g–1 for LC–MS/MS and LC–MS calibration and 20 ng g–1 for LC–FD 172 
calibration) was used as surrogate. The lack–of fit test was used to check the linearity of 173 
the calibration graphs according to the Analytical Methods Committee [13]. Table 1 174 
shows the calibration parameters obtained (intercepts and slopes). 175 
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Table 1 176 
 177 
Methods validation parameters 178 
 179 
Validation of the methods was performed according to the US Food and Drugs 180 
Administration (FDA) guideline for bioanalytical assay procedure [13] in terms of 181 
linearity, selectivity, sensitivity and accuracy (precision and trueness).  182 
Linearity. It was tested using the correlation coefficients (R2) and the P values of 183 
the lack–of–fit test. R2 values ranged from 99.6 to 99.9% for the LC–FD method, from 184 
99.2 to 99.5% for the LC–MS method and from 99.1 to 99.7% for the LC–MS/MS 185 
method. Plof values were higher than 5% in all cases. These facts indicate a good 186 
linearity within the stated ranges.  187 
Selectivity. The specificity of the three methods was determined by comparing the 188 
chromatograms of blank with the corresponding spiked pig muscle samples. No 189 
interferences from endogenous substances were observed at the retention time of the 190 
analytes. 191 
Sensitivity. The limits of detection (LOD) and quantification (LOQ) were 192 
calculated according with the IUPAC criterion [14] and the obtained values are shown 193 
in Table 1.  194 
Accuracy (precision and trueness). To evaluate the overall precision of the 195 
methods, intra– and inter–day precision (as relative standard deviation, RSD) were 196 
estimated at three different concentrations for each compound (25.0, 50.0 and 100.0 ng 197 
g–1 for LC–MS and LC–MS/MS, and 10.0, 20.0 and 40.0 ng g–1 for LC–FD). In the LC–198 
MS and the LC–MS/MS assess, five pig muscle samples were spiked, extracted and 199 
analyzed; in the LC–FD assess three spiked samples were extracted and analyzed in 200 
duplicate. The procedure was repeated three times on the same day to evaluate intra–day 201 
variability and on three consecutive days to determine inter–day variability. Trueness 202 
was evaluated by determining the recovery of known amounts of the tested compounds 203 
in pig muscle samples. Samples were analyzed using the three methods and the 204 
concentration of each compound was determined by interpolation in the standard 205 
calibration curve within the linear dynamic range and compared to the amount of 206 
analytes previously added to the samples. The results of precision and trueness, 207 
summarized in Table 1, fulfill the requirements defined by the EU legislation [7]. 208 
 209 
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Application of the methods 210 
 211 
Six different pig muscle samples purchased in different markets in the area of Granada 212 
(Spain), were extracted, cleaned up and analyzed according to the three methods, in 213 
order to prove the presence or not of quinolones in these tissues destined to human 214 
consumption. The results obtained with the three methods were similar and showed that 215 
one of the analyzed samples contain residues of MAR and OXO. The found 216 
concentration of MAR was 62.0 ng g–1 and of OXO 20.0 ng g–1. Both values are lower 217 
than the MRL established by the EU for these compounds. RSDs from the mean of the 218 
values obtained with the three methods are 2.8% for MAR and 3.6% for OXO. Figures 219 
1, 2 and 3 show the chromatograms of the positive sample using LC–FD, LC–MS (SIM 220 
mode) and LC–MS/MS (MRM mode). 221 
 222 
Figure 1, 2 and 3 223 
 224 
Comparison of methods  225 
 226 
All methods have a good linearity within the stated ranges, especially the LC–FD 227 
method that has the highest values of R2 in all cases. In relation to the selectivity, the 228 
identification of compounds in LC–FD is based on almost exclusively in its retention 229 
time; as well the compound must be fluorescent at particular wavelengths (λexc, λem). In 230 
the case of LC–MS each compound is identified by its retention time and it 231 
characteristic m/z (molecular ion, generally M+H+). On the other hand, in LC–MS/MS 232 
as well as the retention time, the compounds are identified by two characteristic ions; 233 
the first one is used for quantification and the second for confirmation. In this 234 
technique, the ratio between quantification and confirmation ions is also used for the 235 
unequivocal identification of compounds. Therefore the LC–MS/MS method is the most 236 
appropriate from the point of view of selectivity. Related to sensitivity, the lowest LOD 237 
and LOQ were obtained when the LC–MS/MS method was used. The LODs were 238 
between 0.2 and 0.3 ng g–1 for the LC–MS/MS method; between 0.3 and 1.8 ng g–1 for 239 
the LC–MS method and between 0.1 and 2.1 ng g–1 for the LC–FD method. In all cases, 240 
these values are below of the MRL established by the EU in the Commission 241 
Regulation 37/2010 amending Annexes I to IV to Council Regulation (EEC) No 242 
2377/90 on pharmacologically active substances and their classification regarding 243 
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maximum residue limits in foodstuffs of animal origin. However, the values obtained 244 
using the LC–MS/MS method are from 1.5 to 6 times lower than those obtained using 245 
the LC–MS method and from 2 up to 10 times lower than the ones obtained using the 246 
LC–FD method, except for DAN whose LOD and LOQ are lower using the LC–FD 247 
method. Therefore, the LC–MS/MS method is again the best in terms of sensitivity. In 248 
terms of accuracy, intra–day and inter–day precision of the methods were lower than 249 
15% and this is within the acceptable limits proposed by the guidelines for bioanalytical 250 
method validation (≤ 20%). In all cases RSD values for the LC–FD (2–4%) method 251 
were lower than those obtained for the LC–MS (5–14%) and LC–MS/MS (5–12%) 252 
methods. Finally, recoveries were higher than 77% in all cases with the three methods. 253 
The best results were obtained when LC–MS/MS was used as analytical technique, 254 
except for oxolinic acid whose recovery is higher using the LC–FD method.  255 
 256 
 257 
Conclusions 258 
 259 
In this work, three procedures which allow the extraction, identification and 260 
quantification of the quinolones regulated by the EU in pig muscle samples have been 261 
compared. The methods include an extraction of the quinolones from the tissue, a 262 
clean–up step by SPE and separation and determination by LC–MS, LC–MS/MS and 263 
LC–FD detection. The LOD and LOQ of the three methods are much lower than the 264 
MRLs fixed by European Union. The lowest values were obtained when the LC–265 
MS/MS method was used. Comparable values of recoveries were obtained for the three 266 
methods and the best results of precision in terms of RSD were obtained for the LC–FD 267 
method. Therefore, the LC–FD method and the LC–MS/MS method are the ones with 268 
the best quality parameters. However, MS/MS have the important advantage of 269 
allowing the possibility of confirming (selectivity) the presence of these compounds by 270 
means of fragment abundance ratios at rather low concentration levels.  271 
It could be concluded that because of its low cost, easier handling and good 272 
quality parameters the LC-FD method would be a good option for the routine analysis 273 
of quinolones in pig muscle samples and if a positive sample were found, the LC-274 
MS/MS method should be used to confirm and ensure the result. 275 
 276 
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Figure Captions 322 
 323 
Fig. 1  LC–FD. Contaminated sample with MAR and OXO. Concentration: MAR, 64 324 
ng g–1; OXO, 24 ng g–1; and IS, 20 ng g–1. 325 
 326 
Fig. 2 LC–MS in SIM mode. Contaminated sample with MAR and OXO. 327 
Concentration: MAR, 59 ng g–1; OXO, 18 ng g–1; and IS, 400 ng g–1. 328 
 329 
Fig. 3  LC–MS/MS in MRM mode. (A) Contaminated sample with MAR and OXO. (B) 330 
Confirmatory chromatograms of MAR and OXO. Concentration: MAR, 62 ng g–331 
1; OXO, 18 ng g–1; and IS, 400 ng g–1. 332 
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Figure 3 
